KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Prelimi...(mins contributed $23.2 million and$64.2 ...),Health

Date:2/27/2008

mins contributed $23.2 million and $64.2 million of net revenues for the third quarter and nine months of fiscal 2008, up 4.5% and 8.5%, respectively, from the prior year periods. PrimaCare(R) brand remains the #1 filled brand among prescription prenatal vitamins in the United States. During the first nine months of fiscal 2008, the PrimaCare(R) brand captured 52.3% of the growing essential fatty acid (EFA) segment of the branded prescription marketplace, with PrimaCare(R) ONE alone capturing a 45.3% share at the end of December 2007.

Ther-Rx's anemia franchise had total prescriptions grow 4.5% for the first nine months of fiscal 2008 versus the prior year nine-month period and contributed $13.9 million and $37.9 million in net revenues in the third quarter and nine-month periods of fiscal 2008, respectively. Repliva 21/7(TM) remains the #1 branded oral iron product in the United States and reported an 81.6% increase in total prescriptions for the first nine months of fiscal 2008 compared to the prior year period.

During the third quarter, the Company's anti-infective products, Clindesse(R) and Gynazole-1(R), contributed $15.6 million of net sales. Year to date, revenues for the products were $27.8 million and $20.4 million for Clindesse(R) and Gynazole-1(R), respectively, combining for an 18.3% increase from their aggregate net revenues in the corresponding period a year ago.

The Company is prepared for the anticipated launch of Evamist(TM) during the fourth quarter of fiscal 2008. KV believes Evamist(TM), the first estradiol transdermal spray to receive U.S. Food and Drug Administration (FDA) approval, will offer therapeutic effectiveness with estradiol dosing that is among the lowest available for this indication in a manner that is also cosmetically appealing for women. Evamist(TM) targets an annual $1.3 billion estrogen replacement market (Source: IMS NSP Audit, January 2006-December 2006) where patients are seeking an effective and safe, l
'/>"/>

SOURCE KV Pharmaceutical Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine news :

1. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
2. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
3. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
4. Lotus Pharmaceuticals Raises $5 Million in Private Placement
5. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
6. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
7. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
8. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
9. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
10. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
11. KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE